Praxis precision medicines announces topline results from the essential1 study of ulixacaltamide for the treatment of essential tremor and continued advancement of program to phase 3

Based upon observed efficacy and safety profile, praxis intends to engage with the fda in an end of phase 2 meeting and initiate a ulixacaltamide phase 3 study for the treatment of essential tremor in 2h23

PRAX Ratings Summary

PRAX Quant Ranking